Genexine, Inc.

Action · KR7095700001 (XKOS)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur Genexine, Inc.

Pas de cours

Cours de clôture XKOS 29.04.2026: 5.600,00 KRW

29.04.2026 06:30

Cours actuels de Genexine, Inc.

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
KOSDAQ	095700.KQ	KRW	29.04.2026 06:30	5.600,00 KRW	-110,00 KRW -1,93 %

Flottant et Liquidité des Actions

Flottant Libre 74,47 %

Actions en Flottant 33,87 M

Actions en Circulation 45,48 M

Fonds investis

Les fonds suivants ont investi dans Genexine, Inc. :

Fonds iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF USD (Dist)	Vol. en millions 155,56	Part (%) 0,15 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)	Vol. en millions 54,43	Part (%) 0,02 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)	Vol. en millions 275,54	Part (%) 0,02 %

Profil de l'entreprise pour Genexine, Inc. Action

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.